Treatment of E. coli Febrile UTI with Augmentin 625mg TID

Rationale for Augmentin in E. coli UTIs

The American Academy of Pediatrics recommends amoxicillin-clavulanate as an appropriate oral treatment option for UTIs, including febrile UTIs, in clinical practice guidelines 1

The recommended dosage of amoxicillin-clavulanate for UTIs is 20-40 mg/kg per day in 3 doses, which aligns with the 625mg TID dosing for adults, according to the American Academy of Pediatrics 1
Treatment duration for febrile UTIs should be 7-14 days, with 7 days being sufficient when the patient becomes afebrile and clinically improves, as recommended by the European Urology guidelines 1, 2
A shorter course (7 days) may be considered when the patient has been afebrile for at least 48 hours and is hemodynamically stable, according to the European Urology guidelines 2

For complicated UTIs with resistant organisms, amoxicillin-clavulanate is included among the recommended beta-lactam/beta-lactamase inhibitor combinations that can be used when the organism is susceptible, as stated by the Clinical Microbiology and Infection guidelines 3

If the patient fails to respond to Augmentin or has severe infection, consider parenteral therapy with ceftriaxone, cefotaxime, or an aminoglycoside, as recommended by the American Academy of Pediatrics 1
Fluoroquinolones (if local resistance rates are <10%) may be considered as an alternative option, according to the European Urology guidelines 2

Clinical response should be assessed within 48-72 hours of initiating treatment, as recommended by the European Urology guidelines 2
Patients should be monitored for resolution of fever and improvement of urinary symptoms, according to the American Academy of Pediatrics 1
Urine culture and susceptibility testing are essential for guiding definitive therapy, especially in complicated cases or treatment failures, as stated by the Praxis Medical Insights guidelines 4

Failure to obtain urine cultures before initiating antibiotics may lead to inappropriate therapy if the organism has unexpected resistance patterns, as warned by the European Urology guidelines 5
Nitrofurantoin should not be used for febrile UTIs as it does not achieve adequate tissue concentrations to treat upper tract infections, according to the American Academy of Pediatrics 1

The minimum inhibitory concentration (MIC) represents the lowest concentration that inhibits bacterial growth in standardized laboratory conditions, and for amoxicillin-clavulanate, an MIC of 4 mg/L typically falls at or near the susceptibility breakpoint for systemic infections, as stated by the Infectious Diseases Society of America 6, 7
Standard susceptibility breakpoints for amoxicillin-clavulanate vary by testing organization, but an MIC of 4 mg/L is considered borderline susceptible, according to the Clinical and Laboratory Standards Institute 6

For uncomplicated cystitis, the American Academy of Pediatrics recommends amoxicillin-clavulanate 20-40 mg/kg/day in 3 doses as an appropriate option when the organism is susceptible, with a treatment duration of 7 days typically sufficient 8
For febrile UTI/pyelonephritis, the American Academy of Pediatrics suggests parenteral therapy with ceftriaxone 75 mg/kg every 24h or cefotaxime 150 mg/kg/day is preferred when susceptibility is borderline, due to lower tissue penetration into renal parenchyma 8
High bacterial densities at infection sites can result in effective MICs much higher than laboratory testing suggests, making beta-lactam antibiotics like amoxicillin susceptible to the inoculum effect, as noted by the American Heart Association 9

The addition of clavulanate addresses beta-lactamase production but does not overcome all resistance mechanisms, according to the American Academy of Otolaryngology-Head and Neck Surgery 10
An MIC at the breakpoint combined with the inoculum effect means treatment failures are possible, particularly in complicated infections, highlighting the importance of considering pharmacokinetic/pharmacodynamic factors in treatment decisions, as emphasized by the American Heart Association 9